Ignite Creation Date:
2025-12-24 @ 10:37 PM
Ignite Modification Date:
2026-01-01 @ 9:59 AM
Study NCT ID:
NCT03853135
Status:
COMPLETED
Last Update Posted:
2020-01-06
First Post:
2019-02-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Assessment of Endocan Serum Levels in Patients With Behcet Disease
Sponsor:
Benha University
Organization:
Study Overview
Official Title:
Assessment of Endocan Serum Levels in Patients With Behcet Disease: Relation to Clinical Parameters and Disease Status
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of our study was to assess serum endocan levels in patients with Behcet disease and to correlate it with various disease clinical and laboratory parameters of disease activity as well as carotid intima media thickness.
Detailed Description:
This study will be carried out on two groups:
• Group (I): Forty two patients diagnosed to have Behcets disease fulfilling the International Criteria for BD .
Group (II): including 42 age and sex matching healthy volunteers as control group.
(A) Clinical evaluation
1. Complete history taking.
2. Thorough clinical examination including opthalmologic evaluation .
3. Disease activity using The Behcet's disease current activity form (BD-DAF) . (B) Laboratory assessment:
All patients will be subjected to the following measurements:
1. ESR
2. CRP
3. CBC
4. liver and kidney function tests
d) Serum Endocan level e)triglycrides f) cholestrol C) carotid intima media thickness
• Group (I): Forty two patients diagnosed to have Behcets disease fulfilling the International Criteria for BD .
Group (II): including 42 age and sex matching healthy volunteers as control group.
(A) Clinical evaluation
1. Complete history taking.
2. Thorough clinical examination including opthalmologic evaluation .
3. Disease activity using The Behcet's disease current activity form (BD-DAF) . (B) Laboratory assessment:
All patients will be subjected to the following measurements:
1. ESR
2. CRP
3. CBC
4. liver and kidney function tests
d) Serum Endocan level e)triglycrides f) cholestrol C) carotid intima media thickness
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: